Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

650 Search results.

Screening - GSK Milveterol COPD 100527

- 6/18/17 - 1 form, 9 itemgroups, 132 items, 1 language
Itemgroups: Inclusion/Exclusion criteria, Demography, Duration of Asthma, Vital Signs, 12-Lead Electrocardiogram, Pulmonary function, Hematology, Clinical Chemistry, Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Eligibility Lung Neoplasms NCT01717482

- 7/11/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01717482

Eligibility Lung Neoplasms NCT01266512

- 7/11/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01266512

Eligibility Lung Neoplasms NCT01109524

- 7/10/20 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01109524

Eligibility Lung Carcinoma NCT02285660

- 7/10/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition; ODM derived from: https://clinicaltrials.gov/show/NCT02285660

Eligibility Lung Cancer, Non-Small Cell NCT01772225

- 7/10/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
NSCLC Burden of Illness Study; ODM derived from: https://clinicaltrials.gov/show/NCT01772225

Eligibility Lung Cancer NCT02115464

- 7/10/20 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT02115464

Eligibility Lung Cancer NCT02134015

- 7/10/20 - 1 form, 2 itemgroups, 32 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung); ODM derived from: https://clinicaltrials.gov/show/NCT02134015

Eligibility Lung Cancer NCT01594398

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01594398

Eligibility Lung Cancer NCT01562028

- 7/8/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT01562028

Eligibility Lung Cancer NCT01514877

- 7/8/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01514877

Eligibility Lung Cancer NCT00832715

- 7/8/20 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00832715